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Vascular normalization is an emerging concept in cancer treatment. In this issue of Cancer Cell, Rolny et al.
show that histidine-rich glycoprotein normalizes tumor vessels and promotes antitumor immunity by polar-
izing tumor-associated macrophages, leading to decreased tumor growth and metastasis. Placental Growth
Factor deletion in macrophages phenocopies many of these effects.The abnormal vasculature of tumors
impedes the delivery of chemo- and
immunotherapeutic agents and lowers
the barrier for the escape of cancer cells
from tumors. Moreover, the resulting
abnormal microenvironment reduces the
efficacy of radiation, chemo-, and immu-
notherapies, selects for more malignant
clones, and fuels disease progression.
Thus, restoration of the normal structure
and function in blood vessels—coined
as vascular normalization—is emerging
as a new concept in cancer treatment
(Jain, 2001). The normalization strategies
developed to-date have targeted the
abnormalities in the vascular endothelial
cells and/or pericytes (e.g., Hamzah
et al., 2008; Jain, 2005; Mazzone et al.,
2009; Winkler et al., 2004). In this issue
of Cancer Cell, Rolny et al. show that
targeting abnormal polarization of
tumor-associated macrophages (TAMs)
can normalize tumor vessels and also
enhance antitumor immunity (Rolny
et al., 2011)(Figure 1).
TAMs represent a dominant myeloid
population in many solid tumors, and their
accumulation correlates with poor prog-
nosis (Mantovani and Sica, 2010). TAMs
usually exhibit M2-like phenotype,
secreting immunosuppressive cytokines
such as IL-10, CCL17, and CCL22 and
producing proangiogenic and tissue re-
modeling factors such as VEGF, placental
growth factor (PlGF), and MMP9 (Fischer
et al., 2007; Mantovani and Sica, 2010).
Phenotypic subgroups of TAMs often
coexist in the same tumor microenviron-
ment and can be modified by microenvi-
ronmental triggers such as hypoxia.However, a specific therapeutic agent
that could polarize the protumor M2-like
TAMs to tumor-inhibitory M1-like TAMs
remains elusive. Rolny et al. offer
compelling evidence that histidine-rich
glycoprotein (HRG) is such an agent and
that it induces polarization partly by
downregulating macrophage-derived
PlGF (Figure 1).
HRG is a multidomain plasma protein
synthesized by hepatocytes and has
important function in regulation of tumor
angiogenesis and immunity (Blank and
Shoenfeld, 2008). Tumor cells usually
express low levels of HRG. When Rolny
et al. overexpressed HRG in cancer cells,
tumor vessels became normalized, result-
ing in decreased hypoxia and improved
delivery of chemotherapeutic agents and
decreased metastasis (Rolny et al.,
2011). By measuring the production of
cytokines in isolated macrophages and
characterizing their surface markers,
Rolny et al. also found that HRG has
a direct effect on TAMs to polarize them
away from protumoral M2-like phenotype
(Figure 1) (Rolny et al., 2011). Hypoxia,
a hallmark of tumors, is considered to be
a major driving force to polarize macro-
phage to M2-like phenotype (Mantovani
and Sica, 2010). The increase of oxygena-
tion in HRG+ tumors caused by vascular
normalization seems to provide a stimulus
for polarizing TAMs away from M2-like
type, which could further sustain the
normalized vasculature (Rolny et al.,
2011). This positive feedback in the
normalized tumor microenvironment may
confer an additional advantage: extended
window of normalization compared toCancer Cellblockade of VEGF signaling alone (Jain,
2005; Winkler et al., 2004).
Rolny et al. discovered that the sus-
tained vascular normalization by HRG
was also associated with substantially
enhanced antitumor immunity, and, thus,
could potentially explain the decreased
growth of both primary and metastatic
lesions. These effects were presumably
mediated by redirected TAMs to relieve
the immunosuppressive tumor microenvi-
ronment. Exposure of TAMs to HRG
downregulated the M2 markers such as
MRC1, Arg1, IL10, and CCL-22 and
simultaneously elevated M1 markers
such as IL6 and CXCL-9. Accordingly,
tumor-infiltrated CD8+ T cells, natural
killer (NK) cells, and dendritic cells (DCs)
increased and their functions improved
in HRG+ tumors (Rolny et al., 2011).
Reduced levels of CCL22 could decrease
the recruitment of T regulatory cells
(Tregs) and, thus, improve DC and T cell
function. Increased CXCL9 level could
promote CD8+ T cell and NK cell infiltra-
tion into tumor parenchyma. These obser-
vations indicate that re-education of
TAMs links vascular normalization with
restoration of tumor immune surveillance
(Figure 1).
How does HRG skew TAMs away from
M2-like phenotype? Tumors are hetero-
geneous, and numerous players shape
TAM’s phenotypes and function. Rolny
et al. dissect the role of one potential
player, Fcg receptors (FcgRs), expressed
in macrophages that HRG is known to
bind to. Based on preliminary data, Rolny
et al. propose that FcgR may mediate the
polarization of TAMs by HRG. Given that19, January 18, 2011 ª2011 Elsevier Inc. 1
Figure 1. Targeting TAMs to Normalize Tumor Vessels and Promote Antitumor Immunity
TAMs with M2-like phenotype lead to abnormal tumor vasculature by producing angiogenic factors such
as PlGF andM2-cytokines such as IL10 andCCL22. In addition, M2-cytokines suppress immune cell func-
tions. Elevated levels of HRG polarize TAMs away from an M2-like phenotype to normalize tumor vessels
and activate antitumor immunity. By fortifying tumor vessels, vascular normalization may decrease shed-
ding of metastatic cells into circulation, resulting in decreased metastasis. Normalized vessels may also
facilitate delivery of drugs and immune cells. Reduction in hypoxia, known to increase resistance to radi-
ation and a number of therapeutics, also sensitizes tumors to various therapies, decreases selection pres-
sure for more malignant clones, and promotesM1-like TAM phenotype. All these effects of HRG treatment
may result in decreased tumor growth and metastasis and increased efficacy of various therapies. PlGF
deletion in macrophages can phenocopy many effects of HRG treatment. (Schematics of abnormal and
normalized tumor vasculature reproduced from Jain, 2001).
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Previewsinactivation of FcgRs skews macro-
phages to M1-like phenotype (Andreu
et al., 2010), these data suggest that
HRG may serve as an antagonist of
FcgR. It would be of interest to dissect
how different ligands could also induce
distinct context-dependent effects
through different FcgR subtypes. Further
work will answer these questions and
improve our understanding of TAM
polarization.
Rolny et al. also dissected the down-
stream mediators of the HRG activity in
TAMs. By analyzing the cytokines and
angiogenic factors produced by these
cells, they found that HRG reduced PlGF2 Cancer Cell 19, January 18, 2011 ª2011 Elproduction by TAMs. Indeed, the deletion
of PlGF in macrophages phenocopied
antitumor and vascular normalization
effects of HRG treatment (Rolny et al.,
2011). In a previous study by this team,
blocking the TAM-chemo-attractant
PlGF, produced by both tumor and
stromal cells, led to a reduction in macro-
phages in tumors (Fischer et al., 2007).
Since tumor-derived PlGF was not
reduced by HRG and could rescue TAM
infiltration in this study, the current find-
ings also raise an interesting question—
does the effect of HRG depend on the
number of TAMs present in the tumor
microenvironment? The tumor modelssevier Inc.used in this study have a relatively high
number of TAMs. Since other tumors
might have a lower number of TAMs,
whether lower density of TAMs still offers
a therapeutic opportunity for HRG to
normalize vasculature remains to be
explored. Careful dissection of players in
different tumors and context will be
crucial for optimal use of HRG.
In conclusion, this study provides not
only unprecedented insight into the
central role of M2-like TAMs in promoting
vascular abnormalities, tumor metastasis,
and tumor immunosuppression, it also
offers further support for vessel normali-
zation as a new strategy for cancer treat-
ment. By normalizing tumor vasculature
and enhancing antitumor immunity to
suppress tumor growth and metastasis,
HRG opens new avenues for more effec-
tive cancer treatment.REFERENCES
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